2023
Antibiotic therapy is associated with adverse drug events among older adults with advanced cancer: A cohort study
Datta R, Han L, Doyle M, Allore H, Sanft T, Quagliarello V, Juthani-Mehta M. Antibiotic therapy is associated with adverse drug events among older adults with advanced cancer: A cohort study. Palliative Medicine 2023, 37: 793-798. PMID: 36999898, DOI: 10.1177/02692163231162889.Peer-Reviewed Original ResearchConceptsAdverse drug eventsAntibiotic therapyDrug eventsAdvanced cancerOlder adultsIndex admissionPalliative chemotherapyCohort studyTertiary care centerHospitalized older adultsPalliative care providersMultidrug-resistant organismsMean ageCommon tumorsCare centerCare providersRatio of daysSolid tumorsMultivariable testingPatientsTherapyStandardized criteriaCancerMean timeAdults
2019
A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making
Sanft T, Berkowitz A, Schroeder B, Hatzis C, Schnabel C, Brufsky A, Gustavsen G, Pusztai L, Londen G. A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. Breast Cancer Management 2019, 8: bmt22. DOI: 10.2217/bmt-2019-0001.Peer-Reviewed Original Research
2016
Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study.
Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Gross C, Pusztai L, Mougalian S. Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study. Journal Of Clinical Oncology 2016, 34: e18136-e18136. DOI: 10.1200/jco.2016.34.15_suppl.e18136.Peer-Reviewed Original ResearchRecent Updates in the Management of Triple Negative Breast Cancer
Sanft T, Moran M. Recent Updates in the Management of Triple Negative Breast Cancer. TouchREVIEWS In Oncology & Haematology 2016, 12: 36. DOI: 10.17925/ohr.2016.12.01.36.Peer-Reviewed Original ResearchTriple-negative breast cancerNegative breast cancerBreast cancerLocoregional treatment optionsComplete pathologic responseNeoadjuvant chemotherapyPathologic responseResidual diseaseTreatment optionsAggressive subtypeNew agentsCancerDruggable targetsDisease biologyRecent updatesFurther researchChemotherapyPatientsTherapySubtypesDisease
2015
Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.
Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. DOI: 10.1200/jco.2015.33.15_suppl.538.Peer-Reviewed Original Research
2014
Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.
Park E, Abu-Khalaf M, Hatzis C, LaSala J, Silber A, Hofstatter E, Sanft T, Russell R. Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer. Journal Of Clinical Oncology 2014, 32: e11501-e11501. DOI: 10.1200/jco.2014.32.15_suppl.e11501.Peer-Reviewed Original Research
2005
Functional dyspepsia: subgroups, history and outcomes.
Sanft T, Jones M. Functional dyspepsia: subgroups, history and outcomes. Minerva Gastroenterology 2005, 51: 225-34. PMID: 16280964.Peer-Reviewed Original ResearchConceptsIrritable bowel syndromeFunctional dyspepsiaBowel syndromeSymptom-based criteriaPopulation-based studyDyspeptic symptomsPathophysiologic rationaleDyspepsiaSuch symptomsClinical practiceSymptom variabilitySymptomsNatural historyHeterogeneous disorderMost personsSyndromePerson's symptomsTherapyDiagnosisBiochemical explanationDisordersReasonable likelihoodSubstantial overlapPersonsLater date